FIELD: medicine.
SUBSTANCE: invention relates to medicine, namely to methods for correcting the activity of intestinal microbiota in fatty liver disease in an experiment. To do this, modeling fatty liver dystrophy in rats by adding a protein-fat mixture to the standard diet in a ratio of 70:30 in an amount of 12–15 g for 3–3.5 months. Method includes daily, intraperitoneal administration during this time period of serotonin in a dose of 50–100 mcg/kg.
EFFECT: method provides effective correction of the intestinal microbiota in fatty liver disease.
1 cl, 4 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD OF SIMULATING NON-ALCOHOLIC FATTY LIVER DISEASE IN RATS | 2015 |
|
RU2600476C1 |
METHOD OF TREATING NON-ALCOHOLIC FATTY LIVER DISEASE AND TYPE 2 DIABETES MELLITUS | 2018 |
|
RU2706026C1 |
METHOD OF TREATING NON-ALCOHOLIC FATTY LIVER DISEASE | 2013 |
|
RU2537229C1 |
METHOD FOR DIAGNOSING HEPATIC FIBROSIS IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE WITH TYPE 2 DIABETES MELLITUS | 2019 |
|
RU2732526C1 |
ANTYSTEATOSIS AGENT | 2019 |
|
RU2702003C1 |
METHOD OF TREATING STEATOHEPATOSIS IN EXPERIMENTAL ANIMALS | 2023 |
|
RU2811886C1 |
METHOD OF LACTASE DEFICIENCY IN ADULTS TREATMENT | 2017 |
|
RU2684099C1 |
DIAGNOSTIC TECHNIQUE FOR DRUG-INDUCED LIVER INJURY IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE | 2018 |
|
RU2695021C1 |
DIFFERENTIAL DIAGNOSTIC TECHNIQUE FOR HEPATIC STEATOSIS AND STEATOHEPATITIS | 2013 |
|
RU2545990C2 |
METHOD FOR PREDICTING SEVERE HEPATIC FIBROSIS IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE | 2021 |
|
RU2765847C1 |
Authors
Dates
2018-04-06—Published
2017-03-16—Filed